Immunology and Biotherapies
15.4K views | +4 today
Follow
Immunology and Biotherapies
Page Ressources et Actualités du DIU immunologie et biothérapies
Your new post is loading...
Your new post is loading...
Rescooped by Gilbert C FAURE from Top Selling Monoclonal Antibodies 2014
Scoop.it!

Side effects of Immune System Drugs: Cytokines and Monoclonal Antibodies

Side effects of Immune System Drugs: Cytokines and Monoclonal Antibodies | Immunology and Biotherapies | Scoop.it
Abstract

This review of the July 2013 to December 2014 publications on cytokines and monoclonal antibodies covers bone morphogenic proteins, colony-stimulating factors, interferons, interleukins, tumor necrosis factor alfa, adalimumab, certolizumab, etanercept, golimumab, infliximab, abciximab, alemtuzumab, bevacizumab, cetuximab, daclizumab, natalizumab, ranibizumab, rituximab, tocilizumab and trastuzumab.

 

KeywordsAdverse reactions; Cytokines; Monoclonal antibodies; Bone morphogenic proteins;Colony-stimulating factors; Interferons; Interleukins; Tumor necrosis factor alfa;Adalimumab; Certolizumab; Etanercept; Golimumab; Infliximab; Abciximab;Alemtuzumab; Bevacizumab; Cetuximab; Daclizumab; Natalizumab; Ranibizumab;Rituximab; Tocilizumab; Trastuzumab


Via Krishan Maggon
more...
Krishan Maggon 's curator insight, October 10, 2015 8:43 AM
Side Effects of Drugs Annual

Available online 1 October 2015

In Press, Corrected Proof — Note to users

 
Drugs That Act on the Immune System: Cytokines and Monoclonal AntibodiesLokesh K. Jha*, Sandeep Mukherjee†, , 
 
 
 
doi:10.1016/bs.seda.2015.08.006
Rescooped by Gilbert C FAURE from Top Selling Monoclonal Antibodies 2014
Scoop.it!

Humira (adalimumab, AbbVie) remains the top selling human medicinal brand and mab in 2014

Humira (adalimumab, AbbVie) remains the top selling human medicinal brand and mab in 2014 | Immunology and Biotherapies | Scoop.it

REPORTS FULL-YEAR ADJUSTED EPS OF $3.32, UP 5.7 PERCENT; GAAP EPS $1.10- DELIVERS FOURTH-QUARTER ADJUSTED REVENUE OF $5.371 BILLION, UP 8.9 PERCENT OVER FOURTH-QUARTER 2013 (UP 5.1 PERCENT ON A REPORTED BASIS); GAAP REVENUE $5.452 BILLION- REVENUE GROWTH IN THE QUARTER REFLECTS 14.4 PERCENT GLOBAL OPERATIONAL SALES GROWTH FROM HUMIRA (UP 10.6 PERCENT ON A REPORTED BASIS) AND STRONG GROWTH FROM OTHER KEY PRODUCTS- DELIVERS ADJUSTED GROSS MARGIN IMPROVEMENT OF 410 BASIS POINTS IN THE FOURTH QUARTER- REPORTS FOURTH-QUARTER ADJUSTED EPS OF $0.89, UP 8.5 PERCENT; GAAP EPS ($0.51)- LAUNCHES INTERFERON-FREE HCV REGIMEN FOLLOWING APPROVAL IN UNITED STATES, EUROPE AND CANADA- CONFIRMS 2015 ADJUSTED EPS GUIDANCE RANGE, REFLECTING INDUSTRY-LEADING GROWTH VERSUS THE PRIOR YEAR

 

 Global HUMIRA sales increased 10.6 percent, or 14.4 percent on an operational basis, excluding the impact of foreign exchange rate fluctuations.  


Via Krishan Maggon
more...
Krishan Maggon 's curator insight, February 4, 2015 5:07 AM

Humira with 2014 sales of $12.5 billion retains the top selling human medicine for the second year after the patent expiry of Lipitor.  

 

Remicade

Rituxan

Avastin

Herceptin    

 

are the other 5 top selling mabs in 2014.

 

to be updated

Krishan Maggon 's curator insight, February 4, 2015 5:10 AM

Humira with 2014 sales of $12.5 billion retains the top selling human medicine for the second year after the patent expiry of Lipitor.  

 

Sovaldi

Remicade

Enbrel

Rituxan

Avastin

Herceptin

   

 

are the other top selling medicines in 2014.

 

to be updated

Rescooped by Gilbert C FAURE from Top Selling Monoclonal Antibodies 2014
Scoop.it!

Anti-TNF therapy: past, present and future

Anti-TNF therapy: past, present and future | Immunology and Biotherapies | Scoop.it
Abstract

While for a century therapeutics has been dominated by small molecules, i.e. organic chemicals of ~400Da absorbable via the gut, this is no longer the case. There are now a plethora of important medicines which are proteins and injectable, which have dramatically improved the therapy of many inflammatory diseases and of cancer. Most of these are monoclonal antibodies, some are receptor Ig Fc fusion proteins, others are cytokines or enzymes. The key to this new aspect of therapeutics has been the filling of unmet needs, and the consequent commercial success, which promoted further research and development. The first ‘biologic’ for a common disease, rheumatoid arthritis (RA), was a monoclonal antibody, infliximab, to human tumour necrosis factor (TNF). This was based on our work, which is described in this review, summarizing how TNF was defined as a good target in RA, how it was developed is described here, as well as future indications for anti-TNF and related agents. Biologics are now the fastest growing sector of therapeutics.


Via Krishan Maggon
more...
Krishan Maggon 's curator insight, March 3, 2015 12:52 PM
Claudia Monaco, Jagdeep Nanchahal, Peter Taylor, and Marc FeldmannAnti-TNF therapy: past, present and future

Int. Immunol. (2015) 27 (1): 55-62 doi:10.1093/intimm/dxu102

Rescooped by Gilbert C FAURE from Top Selling Monoclonal Antibodies 2014
Scoop.it!

Best Selling Monoclonal Antibodies 2013

Best Selling Monoclonal Antibodies 2013 | Immunology and Biotherapies | Scoop.it

Via Krishan Maggon
Gilbert C FAURE's insight:

impressive for immunologists so far away from so big amounts of money

more...
Krishan Maggon 's curator insight, January 6, 2014 8:38 AM

Abstract

 

A review of the best selling monoclonal antibodies in 2013 and 2012 is provided. Humira with sales of over $11 billion ($9.3 billion in 2012) remains the best selling monoclonal antibody, biologic as well prescription drug brand in 2013 as in 2012. The ranks of the next 4 top selling mabs remained unchanged from the 2012 Table.  Remicade (9.7 Bn), Rituxan (7.5 Bn) , Herceptin (6.5 Bn) and Avastin (6.5 Bn) were the second, third, fourth and fifth top selling mabs in 2013. The actual sales for 2013 as reported by the companies are provided. The total sales of the top selling blockbuster mabs were $63 billion in 2013. The actual global sales of all the approved blockbuster sales or potential (sales >1 billion) monoclonal antibodies in 2013 is provided. Besides the top 5 mabs, there were 2 other monoclonal antibodies with sales of over 2 billion dollars and 5 with sales of over $ 1 billion in 2013. In addition 5 recently launched mabs were nearing to reach sales of $ 1 billion this year. Currently 30 monoclonal antibodies are marketed in the US and Europe (January 2014).  Alexion Soliris was the most expansive marketed monoclonal antibody with a price tag of $440,000 per year of treatment, a sort of Rolls-Royce of mabs.